Novavax to Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing

  • Funds clinical development of NVX-CoV2373 through Phase 2
  • Supports rapid scale-up of vaccine manufacturing
  • Allows for increased production of Matrix-M adjuvant
  • Reserves global large-scale manufacturing capacity

GAITHERSBURG, Md., May 11, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines …

Read More